|Bid||0.00000 x 0|
|Ask||0.00000 x 0|
|Day's Range||0.00000 - 0.00000|
|52 Week Range|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
For large scale adoption of Cannabis in medical formulations the quality, consistency and trust in the raw ingredients is essential in providing a true scientific base line and prove efficacy in the medical world. “This technique allows us to produce healthy, genetically identical copies of prime mother plants resulting in optimal cannabinoid and terpene profiles over multiple grow cycles.
LAS VEGAS, May 22, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), it all started with one woman's plea and ended with a call to action for a dramatic expansion of diseases treated by medical cannabis throughout the State of Louisiana. The passage of the Alison Neustrom Act in 2015 opened the door for a relatively small number of qualified patients to legally receive medical marijuana treatment. The passage of two new House Bills increases the patient count to include patients with additional qualifying disease conditions in the State.
LAS VEGAS, May 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), the previously announced proposed acquisition of NevadaPURE, LLC, a Nevada limited liability company, by GB Sciences has been terminated. In accordance with the terms of the non-binding letter of intent signed between the parties and after the due diligence period (which was mutually extended by one week), GB Sciences and NevadaPURE, LLC mutually agreed not to proceed with the transaction. GB Sciences' Chairman of the Board and CEO John Poss said: "A nondisclosure agreement between the parties prevents GB Sciences from making extensive comments on the proposed transaction.
MIAMI, FL / ACCESSWIRE / May 7, 2018 / Cannabis Investor Magazine , the leading industry investment magazine for cannabis investors, analysts, executives, entrepreneurs, and financial media, announced ...
The company recently announced that it is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease. The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. Furthermore, the transaction also enables GB Sciences with access to three licenses from the state of Nevada for cultivation and production of marijuana along with the one for running a dispensary.
DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...
PHOENIX, April 19, 2018-- GB Sciences, Inc., today announced CEO, John Poss, returned to Uptick Newswire’ s“ Stock Day” podcast with Everett Jolly for an operational update.. “GB Sciences is a cannabis ...
LAS VEGAS, April 17, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX), as previously reported, plans to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data, to support clinical development decisions on prioritizing among multiple, related Parkinson's Disease ("PD") formulations. GB Sciences has a patent application covering multiple, related PD-formulas that are based on complex mixtures of minor cannabinoids and terpenes from cannabis chemovars. In preclinical studies, GB Sciences has demonstrated that complex mixtures of cannabis-based compounds may provide greater clinical benefits than single compound treatments due to molecular synergies for the treatment of Parkinson's.
LAS VEGAS, April 10, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the treatment of early to moderate Parkinson's disease ("PD"). The GB Sciences' Exploratory IND program is designed to allow the company to make informed, data-driven choices in selecting and prioritizing the development of multiple, related drug compositions and formulations. An Exploratory IND requires less pre-clinical data and offers a more flexible way to get essential information about potential drug development candidates than a more conventional early phase development program. Performing an FDA-Registered clinical trial, instead of a Nevada-based pilot trial as reported earlier, also translates to quicker entry into international markets with harmonized regulatory standards.
LAS VEGAS, April 4, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has completed the technology transfer for the manufacturing of time-released nanoparticles containing a cannabinoid-based therapeutic for neuropathic pain from the University of Seville. As announced in Q4 of 2017, GB Sciences has obtained the exclusive worldwide license to the intellectual property covering this time-released cannabinoid formulation from the University of Seville ("USE"), the Centro de Investigación Biomédica en Red de Salud Mental ("CIBERSAM") and the University of Cadiz ("UCA").
LAS VEGAS, March 28, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is extremely pleased to announce it has signed a letter of intent to purchase 100% of the ownership interests of NevadaPURE's Las Vegas operation for $28 million in cash and the assumption of approximately $5 million of outstanding liabilities. The annualized sales run rate of NevadaPURE is over $16 million based on its performance since adult use became legal in Nevada, making the purchase price only two times sales. This sales multiple compares with GB's current price-to-annualized-sales multiple of 16, and a typical multiple of 60 or much more for publicly traded cannabis companies whose sales are similar to GB's.
GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
According to a report by Ameri Research Inc., the global legal cannabis market was valued at $14.3 billion in 2016 and is estimated to grow at a CAGR of 21.1% between 2017 to 2024, while reaching a value of $63.5 billion by 2024. The market is going through a period of robust growth because of increasing legalization and decriminalization of cannabis products across North America. Data by Arcview Market Research clarifies that growth of the legal cannabis industry are expected reaccelerate in 2018, as adult use sales ramp up in Canada, California, and Massachusetts along with medical sales in Florida.
LAS VEGAS, March 15, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce their sponsorship of the 1st Annual "Innovation in Medical Cannabis Therapies" Symposium in Las Vegas, Nevada, on Friday, June 1st, 2018. Top innovators in cannabis tech, biotech, nanotech, and metabolomics are invited to this collaborative discussion, which was designed to explore the necessary advances across multiple fields that are required for the development of safe and effective plant-based medicines. The GBS approach to research is always grounded in solid science and The Life Sciences team, a division of GB Sciences, has discovered that other researches who ascribe to this nontraditional mindset usually find funding and partnering difficult to come by.
LAS VEGAS, Feb. 27, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) is pleased to announce a new agreement with the Colorado Hemp Project to develop and cultivate boutique genetics and new strains of hemp which will provide the key ingredient in proprietary CBD formulations. The mission statement of the Colorado Hemp Project is: an organic hemp farm consulting agency that works with local farmers and municipalities across the globe to bring hemp cultivars and resources to the communities that need it the most, with the sole intention of healing the planet by accelerating the establishment of local, sustainable hemp farms and companies everywhere. GB Sciences believes that hemp will provide an important palette upon which important compounds can be created, and believes that, ultimately, hemp will provide a relatively inexpensive source of important and beneficial cannabinoids.
GB Sciences, Inc. Enters A New Market by Signing a Contract Farming Agreement for the Development of Boutique Hemp Genetics with the Colorado Hemp Project
LAS VEGAS, Feb. 21, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has been issued its production license and now begins full production operations in the Las Vegas, Nevada facility. Production license partners include Relax With Happy™ ("RWH"), a new venture co-founded by veteran cannabis chef, Deliciously Dee™, and Cura Cannabis Solutions, maker of the best-selling cannabis brand on the West Coast, Select Oil.
LAS VEGAS, Feb. 14, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) and its wholly-owned subsidiary GB Sciences Louisiana, LLC. (GBSL) are pleased to announce the completion of a new agreement with Wellcana Group, LLC. (Wellcana) to work together on the previously announced initiative for the development of medical cannabis in Louisiana, a joint effort of the Louisiana State University AgCenter and GBSL, operating under the AgCenter's medical cannabis license, which is one of only two licenses granted by the State. The terms of the agreement provide that Wellcana will buy 15% of the newly-issued equity of GBSL for $3 million. Wellcana also has an option to purchase an additional 35% for an additional $7 million investment.
GB Sciences Partners with Wellcana Group, LLC. in the Development of Medical Cannabis in Louisiana
GB Sciences Files a Nonprovisional Patent Application for Cannabis-Based Anti-Inflammatory Therapies Including Arthritis, Asthma, Eczema and More
LAS VEGAS, Feb. 5, 2018 /PRNewswire/ -- GB Sciences, Inc. (GBLX) has filed a nonprovisional patent application to protect its cannabinoid-containing complex mixtures for the treatment of inflammatory disorders. Inflammatory disorders, such as arthritis, asthma, eczema, psoriasis, Crohn's disease and Inflammatory Bowel Disease, represent a serious health burden in the US with over $200 billion spent annually.
GB Sciences Welcomes Dr. Zoltan Mari, A Nationally Recognized Expert on the Study and Treatment of Parkinson's Disease to Their Scientific Advisory Board